Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER2 | P43116 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.47 |
| ▸ | SENP8 | Q96LD8 | 1/20 | 0.47 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.47 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | DHODH | Q02127 | 1/20 | 0.45 |
| ▸ | BRD4 | O60885 | 1/20 | 0.45 |
| ▸ | KDM4A | O75164 | 1/20 | 0.44 |
| ▸ | KDM5A | P29375 | 1/20 | 0.44 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.44 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.44 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.43 |
| ▸ | FEN1 | P39748 | 1/20 | 0.43 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1566041 | 0.92 | PTGER2 (0.68) | PTGER2ATMDHODH | |
| SCHEMBL23758528 | 0.89 | MAPT (0.47) | PTGER2KDM4EATMCASP3SENP8 | |
| SCHEMBL690024 | 0.86 | PTGER2 (0.59) | PTGER2KDM4EMAPT | |
| SCHEMBL689261 | 0.86 | PTGER2 (0.59) | PTGER2KDM4EMAPT | |
| SCHEMBL6152705 | 0.84 | ALDH1A1 (0.49) | PTGER2KDM4EATMCASP3SENP8 | |
| SCHEMBL12971183 | 0.82 | GSTP1 (0.56) | PTGER2KDM4EDHODH | |
| SCHEMBL20568185 | 0.79 | ALDH1A1 (0.46) | PTGER2KDM4EBRD4 | |
| SCHEMBL3344995 | 0.77 | TUBB4A (0.53) | KDM4EATMMAPT | |
| SCHEMBL19946295 | 0.77 | KDM4E (0.55) | KDM4EATMCASP3SENP8SENP7 | |
| SCHEMBL19350175 | 0.77 | KDM4E (0.49) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1975158-B9 | NOVEL PYRROLE DERIVATIVES WITH HISTONE DEACETYLASE INHIBITOR ACTIVITY | UNIV PAIS VASCO (ES) | 2012-02-29 | — | — | EP | disclosed |
| EP-1975158-B1 | NOVEL PYRROLE DERIVATIVES WITH HISTONE DEACETYLASE INHIBITOR ACTIVITY | UNIV PAIS VASCO (ES) | 2011-07-13 | — | — | EP | disclosed |
| US-7638550-B2 | new compounds derived from formula I pyrroles, methods for obtaining them and their application as drugs in pharmaceutical compositions for the treatment of cancer due to their inhibitory activity on certain histone deacetylases. | Universidad del Pais Vasco-Euskal Herriko Unibertsitatea (UPV-EHU) Fundacion Centro Nacional de Investigaciones Oncologicas Carlos III (CNIO) (ES) | 2009-12-29 | — | — | US | disclosed |
| US-20080262073-A1 | Pyrrolic Derivatives with Histone Deacetylase Inhibitory Activity | FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III (CNIO) (ES) | 2008-10-23 | — | — | US | disclosed |
| EP-1975158-A1 | NOVEL PYRROLE DERIVATIVES WITH HISTONE DEACETYLASE INHIBITOR ACTIVITY | UNIVERSIDAD DEL PAIS VASCO-EUSKAL HERRIKO UNIBERSITATEA (ES) | 2008-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080262073-A1 | Pyrrolic Derivatives with Histone Deacetylase Inhibitory Activity | HDAC1, HDAC11, HDAC5 | PTGER2 3332/4885KDM4E 63/4885ATM 3085/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.